Death Vs. Symptomatic Relief – Weighing Risks And Benefits For Asthma Drugs
When discussing a drug's benefits and risks, there is more to the equation than just death, Judith Kramer, Duke University, pointed out during a meeting of three FDA advisory committees to discuss asthma indications for long-acting beta agonists
You may also be interested in...
When a post-marketing safety signal arises, patients’ perspective of benefit is often drowned out by consumer advocates’ worries about a drug’s risks, the Office of New Drugs director says.
Novartis Foradil Certihaler (formoterol fumarate inhalation powder) is the first victim of a recommendation by several FDA advisory committees to withdraw the asthma indication for formoterol and salmeterol
Three FDA advisory committees recommended the withdrawal of asthma indications for two long-acting beta agonists - GlaxoSmithKline's Serevent (salmeterol) and Novartis's Foradil (formoterol) -during a Dec. 11 meeting